Thyroid hormone and blood pressure regulation

Current Hypertension Reports

Volumn 5, Issue 6, 2003, Pages 513-520

  Danzi, Sara ^a   Klein, Irwin ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PROPRANOLOL; THIAMAZOLE; THYROID HORMONE;

ADAPTATION; BASAL METABOLIC RATE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; DISEASE ASSOCIATION; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HOMEOSTASIS; HORMONE ACTION; HUMAN; HYPERTENSION; HYPERTHYROIDISM; HYPOTHYROIDISM; PATHOGENESIS; PULSE PRESSURE; REVIEW; TACHYCARDIA; THYROID DISEASE; VASCULAR RESISTANCE;

EID: 3142552579     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-003-0060-7     Document Type: Review

References (81)

1. Dernellis J, Panaretou M: Effects of thyroid replacement therapy on arterial blood pressure in patients with hypertension and hypothyroidism. Am Heart J 2002, 143:718-724.
2. Klein I, Ojamaa K: Thyroid hormone and blood pressure regulation. In Hypertension: Pathophysiology, Diagnosis and Management. Edited by Laragh JH, Brenner BM. New York: Raven Press; 1995:2247-2262.
3. Fletcher AK, Weetman AP: Hypertension and hypothyroidism. J Hum Hypertens 1998, 12:79-82.
4. Parry CH: Collections from the unpublished papers of the late Caleb Hilliel Parry. Dis Heart 1825, 2:111-165.
5. Anderson GW, Mariash CN, Oppenheimer JH: Molecular actions of thyroid hormone. In Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text, edn 8. Edited by Braverman LE, Utiger RD. Philadelphia: Lippincott, Williams & Wilkins; 2000:174-195.
6. Klein I, Ojamaa K: Thyroid hormone and the cardiovascular system. N Engl J Med 2001, 344:501-509.
7. Levey GS, Klein I: Disorders of the thyroid. In Internal Medicine, edn 5. Edited by Stein JH. St. Louis: Mosby; 1998:1323-1349.
8. Zhang J, Lazar MA: The mechanism of action of thyroid hormones. Annu Rev Physiol 2000, 62:439-466.
9. Mintz G, Pizzarello R, Klein I: Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment. J Clin Endocrinol Metab 1991, 73:146-150.
10. Koss KL, Kranias EG: Phospholamban: a prominent regulator of myocardial contractility. Circ Res 1996, 79:1059-63.
11. Davis PJ, Davis FB: Nongenomic actions of thyroid hormone on the heart. Thyroid 2002, 12:459-466.
12. Klein I: Clinical, metabolic, and organ-specific indices of thyroid function. In Endocrinology and Metabolism Clinics, vol 30 Edited by Ross DS. Philadelphia: WB Saunders; 2001:415-427.
13. Goglia F, Silvestri E, Lanni A: Thyroid hormones and mitochondria. Biosci Rep 2002, 22:17-32.
14. Wrutniak-Cabello C, Casas F, Cabello G: Thyroid hormone action in mitochondria. J Mol Endocrinol 2001, 26:67-77.
15. Mutvei A, Husman B, Andersson C, et al.: Thyroid hormone and not growth hormone is the principal regulator of mammalian mitochondrial biogenesis. Acta Endocrinologica 1989, 121:235-228.
16. Klein I: Thyroid hormone and the cardiovascular system. Am J Med 1990, 88:631-637.
17. Polikar R, Burger AG, Scherrer U, et al.: The thyroid and the heart. Circulation 1993, 87:1435-1441.
18. Biondi B, Palmieri EA, Lombardi G, et al.: Effects of thyroid hormone on cardiac function: the relative importance of heart rate, loading conditions, and myocardial contractility in the regulation of cardiac performance in human hyperthyroidism. J Clin Endocrinol Metab 2002, 87:968-974.
19. Graettinger JS, Muenster JJ, Selverstone LA, et al.: A correlation of clinical and hemodynamic studies in patients with hyperthyroidism with and without congestive heart failure. J Clin Invest 1959, 38:1316-1327.
20. Graettinger JS, Muenster JJ, Checchia CS, et al.: A correlation of clinical and hemodynamic studies in patients with hypothyroidism. J Clin Invest 1957, 37:502-510.
21. Obuobie K, Smith J, Evans LM, et al.: Increased central arterial stiffness in hypothyroidism. J Clin Endocrinol Metab 2002, 87:4662-4666.
22. Park KW, Kai HB, Ojamaa K, et al.: The direct vasomotor effect of thyroid hormones on rat skeletal muscle resistance arteries. Anesth Analg 1997, 85:734-738.
23. Giannattasio C, Rivolta MR, Failla M, et al.: Large and medium sized artery abnormalities in untreated and treated hypothyroidism. Eur Heart J 1997, 18:1492-1498.
24. Napoli R, Biondi B, Guardasole V, et al.: Impact of hyperthyroidism and its correction on vascular reactivity in humans. Circulation 2001, 104:3076-3080.
25. Toft AD, Boon NA: Thyroid disease and the heart. Heart 2000, 84:455-460.
26. Villabona C, Sahun M, Roca M, et al.: Blood volumes and renal function in overt and subclinical primary hypothyroidism. Am J Med Sci 1999, 318:277-280.
27. Buccino RA, Spann JF, Pool PE, et al.: Influence of the thyroid state on the intrinsic contractile properties and energy stores of the myocardium. J Clin Invest 1967, 46:1669-1682.
28. Amidi M, Leon DF, deGroot J, et al.: Effect of the thyroid state on myocardial contractility and ventricular ejection rate in man. Circulation 1968, 38:229-239.
29. Ojamaa K Sabet A, Kenessey A, et al.: Regulation of rat cardiac Kv1.5 gene expression by thyroid hormone is rapid and chamber specific. Endocrinology 1999, 140:3170-3176.
30. Klein I, Hong C: Effects of thyroid hormone on cardiac size and myosin content of the heterotopically transplanted rat heart. J Clin Invest 1986, 77:1694-1698.
31. Sugden PH, Clerk A: Cellular mechanisms of cardiac hypertrophy. J Mol Med 1998, 76:725-746.
32. Coleman PS, Parmacek MS, Lesch M, et al.: Protein synthesis and degradation during regression of thyroxine-induced cardiac hypertrophy. J Mol Cell Cardiol 1989, 21:911-925.
33. Klein I: Thyroxine-induced cardiac hypertrophy: time course of development and inhibition by propranolol. Endocrinology 1988, 123:203-210.
34. Biondi B, Palmieri EA, Fazio S, et al.: Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab 2000, 85:4701-4705.
35. Parle JV, Maisonneuve P, Shepard MC, et al.: Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 2001, 358:861-865.
36. Savage DD, Levy D, Dannenberg AL, et al.: Association of echocardiographic left ventricular mass with body size, blood pressure and physical activity (the Framingham Study). Am J Cardiol 1990, 65:371-376.
37. Levy D, Garrison RJ, Savage DD, et al.: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990, 322:1561-1566.
38. Ventrella SM, Klein I: Beta-adrenergic receptor blocking drugs in the management of hyperthyroidism. Endocrinologist 1994, 4:391-399.
39. Ojamaa K, Klein I, Sabet A, et al.: Changes in adenylyl cyclase isoforms as a mechanism for thyroid hormone modulation of cardiac beta-adrenergic receptor responsiveness. Metabolism 2000, 49:275-279.
40. Hoit BD, Khoury SF, Shao Y, et al.: Effects of thyroid hormone on cardiac b-adrenergic responsiveness in conscious baboons. Circulation 1997, 96:592-598.
41. Stevenson LW. Beta-blockers for stable heart failure. N Engl J Med 2002, 346:1346-1347.
42. Rockman HA, Koch WJ, Lefkowitz RJ: Cardiac function in genetically engineered mice with altered adrenergic receptor signaling. Am J Physiol Heart Circ Physiol 1997, 272:H1553-H1559.
43. Resnick LM, Laragh JH: Plasma renin activity in syndromes of thyroid hormone excess and deficiency. Life Sci 1982, 30:585-588.
44. Kobori H, Hayashi M, Saruta T: Thyroid hormone stimulates renin gene expression through the thyroid hormone response element. Hypertension 2001, 37:99-104.
45. Marcisz C, Jonderko G, Kucharz EJ: Influence of short-time application of a low sodium diet on blood pressure in patients with hyperthyroidism or hypothyroidism during therapy. Am J Hypertens 2001, 14:995-1002.
46. Durocher D, Grepin C, Nemer M: Regulation of gene expression in the endocrine heart. Recent Prog Horm Res 1998, 53:7-23.
47. Lewicki JA, Protter AA: Physiological studies of the natriuretic peptide family. In Hypertension: Pathophysiology Diagnosis and Management. Edited by Laragh JH, Brenner BM. New York: Raven Press; 1995:1029-1053.
48. Argentin S, Drouin J, Nemer M: Thyroid hormone stimulates rat pro-natriodilantin mRNA levels in primary cardiocyte cultures. Biochem Biophys Res Commun 1987, 146:1336-1341.
49. Ladenson PW, Bloch KD, Seidman JG: Modulation of atrial natriuretic factor by thyroid hormone: messenger ribonucleic acid and peptide levels in hypothyroid, euthyroid, and hyperthyroid rat atria and ventricles. Endocrinology 1988, 123:652-657.
50. Vesely DL: Atrial natriuretic peptide prohormone gene expression: hormones and diseases that upregulate its expression. IUBMB Life 2002, 53:153-159.
51. Liang F, Webb P, Marimuthu A, et al.: Triiodothyronine increases brain natriuretic peptide (BNP) gene transcription and amplifies endothelin-dependent bnp gene transcription and hypertrophy in neonatal rat ventricular myocytes. J Biol Chem 2003, 278:15073-15083.
52. Cesareo R, Tarabuso A, Di Benedetto M, et al.: Plasmatic endothelin-1 levels in hyperthyroid patients before and after antithyroid therapy. Minerva Endocrinol 2000, 25:1-3.
53. Tilly N, Schneider JG, Leidig-Bruckner G, et al.: Endothelin-1 levels in patients with disorders of the thyroid gland. Exp Clin Endocrinol Diabetes 2003, 111:80-84.
54. Lam HC, Lee JK, Lai KH, et al.: Plasma endothelin levels are unaltered by thyroid hormone status in humans. J Cardiovasc Pharmacol 2000, 36:S382-S385.
55. Baumgartner-Parzer SM, Wagner L, Reining G, et al.: Increase by tri-iodothyronine of endothelin-1, fibronectin and von Willebrand factor in cultured endothelial cells. J Endocrinol 1997, 154:231-239.
56. Imai T, Hirata Y, Iwashina M, et al.: Hormonal regulation of rat adrenomedullin gene in vasculature. Endocrinology 1995, 136:1544-1548.
57. Isumi Y, Shoji H, Sugo S, et al.: Regulation of adrenomedullin production in rat endothelial cells. Endocrinology 1998, 139:838-846.
58. Tomoda Y, Kikumoto K, Isumi Y, et al.: Cardiac fibroblasts are major production and target cells of adrenomedullin in the heart in vitro. Cardiovasc Res 2001, 49:721-730.
59. Taniyama M, Kitamura K, Ban Y, et al.: Elevated plasma adrenomedullin level in hyperthyroidism. Eur J Clin Invest 1996, 26:454-456.
60. Saito I, Kunihiko I, Saruta T: Hypothyroidism as a cause of hypertension. Hypertension 1983, 5:112-115.
61. Canaris GJ, Manowitz NR, Mayor G, et al.: The Colorado thyroid disease prevalence study. Arch Intern Med 2000, 160:526-534.
62. Streeten DHP, Anderson GH Jr, Howland T, et al.: Effects of thyroid function on blood pressure: recognition of hypothyroid hypertension. Hypertension 1988, 11:78-83.
63. Attarian E: Myxedema and hypertension. NY State J Med 1963, 63:2801-2804.
64. Endo T, Komiya I, Tsukui T, et al.: Reevaluation of possible high incidence of hypertension in hypothyroid patients. Am Heart J 1979, 98:684-688.
65. Lerman J, Clark RJ, Means JH: The heart in myxedema: electrocardiograms and roentgen-ray measurements before and after therapy. Ann Intern Med 1933, 6:1251-1271.
66. Saruta T, Kitajima W, Hayashi M, et al.: Renin and aldosterone in hypothyroidism: relation to excretion of sodium and potassium. Clin Endocrinol 1980, 12:483-489.
67. Thompson WO, Dickie LFN, Morris AE, et al.: The high incidence of hypertension in toxic goiter and I myxedema. Endocrinology 1931, 15:265-272.
68. Watanakunakorn C, Hodges RE, Evans TC: Myxedema: a study of 400 cases. Arch Intern Med 1965, 1161:183-190.
69. Cappola AR, Ladenson PW: Hypothyroidisin and atherosclerosis. J Clin Endocrinol Metab 2003, 88:2438-2444.
70. Christ-Crain M, Meier C, Guglielmetti M, et al.: Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. Atherosclerosis 2003, 166:379-186.
71. Hak AE, Pols HAP, Visser TJ, et al.: Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: The Rotterdam Study. Ann Intern Med 2000, 132:270-278.
72. Saito I, Saruta T: Hypertension in thyroid disorders. Endocrinol Metab Clin N Am 1994, 23:379-386.
73. Virtanen VK, Saha HHT, Groundstroem KWE, et al.: Thyroid hormone substitution therapy rapidly enhances left-ventricular diastolic function in hypothyroid patients. Cardiology 2001, 96:59-64.
74. Klein I, Levey GS: The cardiovascular system in thyrotoxicosis. In Werner & Ingbar's The Thyroid: A Fundamental and Clinical Text, edn 8. Edited by Braverman LE, Utiger RD. Philadelphia: Lippincott Williams &Wilkins; 2000:596-604.
75. Sawin CT, Geller A, Wolf PA, et al.: Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994, 331:1249-1252.
76. Marvisi M, Brianti M, Marani G, et al.: Hyperthyroidism and pulmonary hypertension. Respir Med 2002, 96:215-220.
77. Curnock AL, Dweik RA, Higgins BH, et al.: High prevalence of hypothyroidism in patients with primary pulmonary hypertension. Am J Med Sci 1999, 318:289-292.
78. Yanai-Landau H, Amital H, Bar-Dayan Y, et al.: Autoimmune aspects of primary pulmonary hypertension. Pathobiology 1995, 63:71-75.
79. Thurnheer R, Jenni R, Russi EW, et al.: Hyperthyroidism and pulmonary hypertension. J Intern Med 1997, 242:185-188.
80. Petkov V, Mosgoeller W, Ziesche R: Vasoactive intestinal peptide as a new drug for treatment of pulmonary hypertension. J Clin Invest 2003, 111:1339-1346.
81. Henning RJ, Sawmiller DR: Vasoactive intestinal peptide: cardiovascular effects. Cardiovasc Res 2001, 27-37.